about
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanc...
Read More
3.06
0.02
(0.66%)
1.6M
XNAS Volume
XNAS 25 Sep, 2026 2:03 PM (EDT)
Board Meeting
The board meeting for Altimmune Inc is scheduled for today, for the purpose of Altimmune Inc Annual General Meeting for 2026
See details
Not Eligible
Expensive Valuation
Technically Neutral
Altimmune Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..